

Participant Needs, Diversity, and Equity

Sara J. Knight, PhD

Division of Preventive Medicine

University of Alabama at Birmingham

Birmingham VA Medical Center

Implementing and Evaluating Genomic Screening Programs in
Health Care Systems—a Workshop

November 1, 2017

Acknowledgements and disclaimers

The material in this presentation was supported in part by the Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development Service, the National Cancer Institute, and the National Human Genome Research Institute.

The views expressed in this presentation represent the views of the presenter and do not necessarily reflect the position or the policy of the Department of Veterans Affairs, the National Cancer Institute, the National Human Genome Research Institute, or the United States Government.

Preferences for Genetic Testing to Identify Hereditary Colorectal Cancer: Perspectives of High-Risk Patients, Community Members, and Clinicians

Judith Walsh • Millie Arora • Christina Hosenfeld •
Uri Ladabaum • Miriam Kuppermann • Sara J. Knight

- Patients and Public
 - Interest, willing to pay
 - Concern false negatives
 - Perceived health benefits of genetics
- Clinicians
 - Guideline focus
 - Concern about patient/family anxiety
 - Concern about downstream harms

Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample

Sara J. Knight, PhD, Ateesha F. Mohamed, MA, Deborah A. Marshall, PhD, Uri Ladabaum, MD, MS, Kathryn A. Phillips, PhD, Judith M. E. Walsh, MD, MPH

- Web-enabled survey, including a discrete choice experiment
- Probability-based online panel of US residents age 50 and older
- 355 participants completed the survey in April 2010

Predicted Uptake: Best test/Worst test

Improvement	Mean Predicted Uptake	Lower 95% CI	Upper 95% CI
Best test	97%	95%	99%
No test	3%	1%	5%
Worst test	41%	25%	57%
No test	59%	43%	75%

Best Results shared with primary care doctor
0% false negative

Worst Results shared with life and health insurance
20% false negative

Incorporating Genomics in Routine Care for Veterans with Colorectal Cancer

Retrospective cohort

How is genomic data incorporated into routine care of CRC patients


Key Informant Interviews

Barriers and facilitators of routine genomic services for CRC patients

Clinical and demographic characteristics

	N=886 (range or %)
Age	46 (19-55)
Male	812 (92)
Race	
White	518 (62)
African American	298 (35)
Tumor Stage	
0 to 1	196 (25)
2	196 (25)
3	227 (28)
4	181 (23)
Surgical resection	780 (88)
Chemotherapy	555 (63)

Trend in molecular analysis of tumor tissue from 2003 through 2010





Journal of
*Personalized
Medicine*



Article

Barriers and Facilitators to Adoption of Genomic Services for Colorectal Care within the Veterans Health Administration

Nina R. Sperber ^{1,2,*}, Sara M. Andrews ¹, Corrine I. Voils ^{1,2}, Gregory L. Green ³,
Dawn Provenzale ⁴ and Sara Knight ^{5,6}

Molecular testing of tumor--advantageous and available, but seldom used

- Most clinicians see few cases of younger patients diagnosed with CRC
- No request and approval routines
- Low cost of testing is advantageous

Desire for expert support, but variable access

- No standard referral process for consultation
- Need expertise to talk with patients about genetics and genomics
- Little awareness of where to obtain expertise, such as genetic counseling
- But, clinical geneticists and genetic counselors perceived as valuable

Aligning policy and healthcare services for return of results with genome sequencing with the values and preferences of diverse Veterans

- What do Veterans from diverse groups want to learn about from genome sequencing? Secondary findings from diagnostic evaluation? Research results?
- Do Veterans want only medically actionable results? What else would they want to learn about from genome sequencing?
- What are the optimal healthcare services for the delivery of Veteran-centered return of results from Whole Genome Sequencing?

Limitations of patient engagement methods to improve health services design

- Community outreach creates interest, but potentially **overlooks reluctance** to participate
- Advisory committees can promote **tokenism**
- Typical focus groups may capture initial and intuitive responses to an issue, **potentially superficial**
- Responses to surveys **not deeply informed**
- Consensus panel methods force **premature agreement**

Addressing study design challenges

- Population-based sample of Veterans with sufficient sample size to examine differences in values and preferences of subgroups
- Early study that comprehensively engages patients and key healthcare system decision makers at a national level in setting priorities for return of results from WGS.
- Diverse Veterans will have a voice in and will contribute to shaping how genomic healthcare services are delivered in VA.

Aim 1

Interview Veterans

Build the survey

Test survey:
Veteran relevance

Aim 2

Assemble national
sample of Veterans

Survey Veterans


Analyze survey
data

Aim 3

Integrate interview
& survey
information

Educate VA leaders
about results

Identify priorities:
Veteran-centered
genomics



Aligning genomic health services with values and preferences of diverse Veterans


- Need for a **multi-way, iterative dialogue** between people impacted by the policy, researcher, and policy maker
- **Transparency and accountability** to the Veterans
- Policies developed with public participation perceived as more **legitimate, trusted, and likely to be implemented** than those without engagement

Democratic deliberation

- Method for public input on policies
- Includes education and interaction with other citizens and experts
- Participants are able to provide feedback and input on policies that are informed by thorough reflection



Multi-level, multi-process stakeholder engagement



Contact information

Sara J. Knight, PhD

University of Alabama at Birmingham

Birmingham VA Medical Center

sjknight@uab.edu